Bioblast Pharma

Hope should not be rare

Trial-related news archive

Trial-related News Archive

  • October 27, 2014
  • Bioblast Pharma
  • Trial-related news

Bioblast Pharma Announces Initiation of Its Canadian OPMD Clinical Study Center at McGill University, Montreal

TEL AVIV, Israel, Sept. 22, 2014 (GLOBE NEWSWIRE) — Bioblast Pharma Ltd (ORPN), a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases, announced today it has received Health Canada approval to begin enrolling patients at the Montreal Neurological Institute at McGill University for its HOPEMD Phase 2/3 study investigating Cabaletta in patients with Occulopharyngeal Muscular Dystrophy (OPMD). Professor Bernard Brais, co-director of the neuromuscular group of the Montreal Neurological Institute and Hospital, is the principal investigator of the study in Canada.

Continue reading

  • September 21, 2014
  • Bioblast Pharma
  • Trial-related news

Bioblast Pharma Announces Preclinical and Clinical Pharmacokinetic Results with Cabaletta, Interim Safety Results from Phase 2/3 HOPEMD Study in OPMD

Interim Data on First 11 Patients in the Ongoing Phase 2/3 HOPEMD Study Suggest Cabaletta to be Safe and Well Tolerated with No Drug Related Adverse Events

TEL AVIV, Israel, September 17, 2014 – Bioblast Pharma Ltd (NasdaqGM: ORPN),
a clinical-stage biotechnology company committed to developing clinically meaningful

therapies for patients with rare and ultra-rare genetic diseases, announced today positive preclinical and clinical pharmacokinetic (PK) data on Cabaletta, its drug candidate for patients suffering from oculopharyngeal muscular dystrophy (OPMD). The Company also announced interim safety results from the ongoing Phase 2/3 HOPEMD study in OPMD.

Continue reading

Pages